Literature DB >> 12764051

Parkin disease: a phenotypic study of a large case series.

Naheed L Khan1, Elizabeth Graham, Peter Critchley, Anette E Schrag, Nicholas W Wood, Andrew J Lees, Kailash P Bhatia, Niall Quinn.   

Abstract

Mutations in the parkin gene, PARK2, are a common cause of parkinsonism in familial as well as isolated cases with an age of onset <40 years and should be considered in the diagnostic work up of young-onset parkinsonism. We report a detailed clinical evaluation of a personal series of 24 patients with mutations in the parkin gene. The clinical presentation of most cases was broadly comparable to that of previous descriptions of autosomal recessive early-onset or juvenile parkinsonism and young-onset Parkinson's disease and also had similarities with phenotypes of dopa-responsive dystonia. However, our only case with consanguineous parents had an age of onset of 54 years. We report three new phenotypes at presentation: cervical dystonia; autonomic dysfunction and peripheral neuropathy; and pure exercise-induced dystonia. We emphasize a number of clinical features that can be seen in parkin disease: focal dystonia; early instability; freezing; festination or retropulsion; concurrent autonomic failure; dramatic response to anticholinergics; early or atypical L-dopa-induced dyskinesias; exquisite sensitivity to small doses of L-dopa; and recurrent psychosis, even taking L-dopa alone. We also report behavioural disorder prior to the onset of parkinsonism. Some relatives carrying a single parkin mutation without extrapyramidal symptoms or signs also had psychiatric symptoms that might be related to their carrier status.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764051     DOI: 10.1093/brain/awg142

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  95 in total

1.  The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Authors:  Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  Myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations.

Authors:  Anna De Rosa; Teresa Pellegrino; Sabina Pappatà; Maria Teresa Pellecchia; Silvio Peluso; Francesco Saccà; Paolo Barone; Alberto Cuocolo; Giuseppe De Michele
Journal:  J Nucl Cardiol       Date:  2015-12-01       Impact factor: 5.952

3.  Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.

Authors:  Günes Kiziltan; Sibel Ozekmekçi; Sibel Ertan; Turan Ertan; Ethem Erginöz
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

4.  Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.

Authors:  Chiara Fabbri; Concetta Crisafulli; Raffaella Calati; Diego Albani; Gianluigi Forloni; Marco Calabrò; Rosalba Martines; Siegfried Kasper; Joseph Zohar; Alzbeta Juven-Wetzler; Daniel Souery; Stuart Montgomery; Julien Mendlewicz; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-04       Impact factor: 5.270

5.  Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations.

Authors:  Susanne Steinlechner; Jessica Stahlberg; Birgit Völkel; Ana Djarmati; Johann Hagenah; Anja Hiller; Katja Hedrich; Inke König; Christine Klein; Rebekka Lencer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-03       Impact factor: 10.154

6.  Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Authors:  Elise Caccappolo; Roy N Alcalay; Helen Mejia-Santana; Ming-X Tang; Brian Rakitin; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Lucien J Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Andrew D Siderowf; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  J Int Neuropsychol Soc       Date:  2010-11-24       Impact factor: 2.892

7.  Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease.

Authors:  Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne A Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Peter V Rabins; Howard D Weiss; Laura Marsh
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

Review 8.  Progress in the pathogenesis and genetics of Parkinson's disease.

Authors:  Yoshikuni Mizuno; Nobutaka Hattori; Shin-Ichiro Kubo; Shigeto Sato; Kenya Nishioka; Taku Hatano; Hiroyuki Tomiyama; Manabu Funayama; Yutaka Machida; Hideki Mochizuki
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-06-27       Impact factor: 6.237

9.  A multidisciplinary study of patients with early-onset PD with and without parkin mutations.

Authors:  E Lohmann; S Thobois; S Lesage; E Broussolle; S Tezenas du Montcel; M-J Ribeiro; P Remy; A Pelissolo; B Dubois; L Mallet; P Pollak; Y Agid; A Brice
Journal:  Neurology       Date:  2008-11-05       Impact factor: 9.910

Review 10.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.